For Clinics

Bring patient-specific dosing to your nuclear medicine department.

YSOTOPE integrates into existing theranostics workflow without disrupting established protocols. Your team keeps using the systems it already knows.

Apply for the Pilot View the Platform
Oncology specialist at clinical workstation in a softly lit hospital consultation room
Workflow Integration

Fits the session schedule your department already runs.

YSOTOPE slots into the clinical workflow at the point where the dosimetrist would otherwise begin manual time-activity curve extraction. The scan arrives via DICOM, YSOTOPE processes it, and the dose report is available before the prescribing decision.

  1. Scan acquired and sent to PACS as normal
  2. YSOTOPE ingests DICOM automatically via PACS integration
  3. AI organ segmentation and quantification runs in background
  4. PK model fitted to available time points
  5. Dose report attached to the originating study in PACS
  6. Prescribing oncologist reviews report before activity decision
Regulatory and Data

Designed for regulated clinical environments.

YSOTOPE is built with the regulatory and data-protection requirements of European oncology departments in mind.

CE Marking Pathway

YSOTOPE is developed with CE Medical Device Regulation controls in mind. Our quality management system is structured to the requirements of the CE pathway for clinical decision-support software.

GDPR Data Processing

A full Data Processing Agreement is in place for all pilot partners. Patient scan data is anonymised at ingestion point. No identifiable data leaves the partner's jurisdiction without explicit consent and legal basis.

Anonymised Processing

Patient-identifying DICOM tags are stripped before YSOTOPE processes imaging data. Dose reports are returned anonymised and matched back to the patient record by the clinic's own system.

Data Residency

Processing infrastructure is hosted within the EU. Partner institutions can specify data residency requirements within the EEA in the Data Processing Agreement.

Pilot Results

Early-access pilot data.

From our early-access pilot programme across three oncology centres in Europe, 74 patient scans processed.

31%
Dose accuracy improvement

Mean reduction in deviation from personalised absorbed dose window vs population-average activity prescription.

4.2 h
Time saved per patient

Manual time-activity curve extraction and PK fitting replaced by automated YSOTOPE processing. Time measured from scan receipt to dose report availability.

89%
Within personalised dose window

Proportion of patients whose prescribed activity fell within the patient-specific therapeutic window as defined by the YSOTOPE dose model.

Join the Pilot

We are accepting a limited cohort of oncology centre partners for our 2026 pilot programme.

Pilot partners receive a dedicated onboarding session, direct access to the YSOTOPE dosimetry team, and joint authorship consideration on any clinical findings. We are prioritising departments with active theranostics programmes and SPECT-capable gamma cameras.

Apply for the Pilot Talk to the Clinical Team

Limited pilot capacity. Applications reviewed within 5 business days.